Evaluating patient preferences for long-acting growth hormone treatments
Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH
This study is trying to see if kids who currently take daily growth hormone shots would be open to switching to a new treatment that only needs to be given less often.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 1 Day to 18 Years |
| Sex | All |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain Academic / other |
| Locations | 1 site (Brussels, Woluwe-saint-lambert) |
| Trial ID | NCT06542809 on ClinicalTrials.gov |
What this trial studies
This study assesses the willingness of pediatric patients currently receiving daily recombinant human growth hormone (rhGH) to switch to long-acting growth hormone (LAGH) treatments. By utilizing questionnaires, the study aims to gather insights on patient preferences and potential barriers to transitioning to LAGH therapies, which require less frequent administration. The focus is on patients with growth hormone deficiency and other related conditions who are already on rhGH treatment. The findings could help inform treatment decisions and improve adherence to growth hormone therapies.
Who should consider this trial
Good fit: Ideal candidates are Belgian and Luxembourgish children aged 0-18 currently receiving rhGH treatment for growth hormone deficiency or related conditions.
Not a fit: Patients who are not currently on rhGH treatment or those outside the specified age range may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment adherence and better growth outcomes for pediatric patients with growth hormone deficiency.
How similar studies have performed: Previous studies on long-acting growth hormone analogues have shown promising results, indicating that this approach is supported by existing evidence.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Belgian and Luxembourgish patients currently under rhGh treatment in its various official indications (as per the Belgian RIZIV/INAMI monitor : growth hormone deficiency, Turner Syndrome, chronic renal insufficiency, Prader-Willi syndrome, Small for gestational age, Noonan Syndrome, SHOX gene deficiency) and included in the BELGROW Registry * Male -female * 0-18 years * Free written or e-consent and oral consent Exclusion Criteria: * No exclusion criteria
Where this trial is running
Brussels, Woluwe-saint-lambert
- Cliniques Universitaires Saint-Luc — Brussels, Woluwe-saint-lambert, Belgium (Recruiting)
Study contacts
- Principal investigator: Philippe Lysy, MD, PhD — Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Study coordinator: Philippe Lysy, MD, PhD
- Email: philippe.lysy@saintluc.uclouvain.be
- Phone: 027641370
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.